SEARCH

SEARCH BY CITATION

REFERENCES

  • American Cancer Society (ACS). 2000. Cancer facts and figures.
  • Andres JL, Fan S, Turkel GJ, Wang JA, Twu NF, Yuan RQ, Lamszus K, Goldberg ID, Rosen EM. 1998. Regulation of BRCA1 and BRCA2 expression in human breast cancer cells by DNA-damaging agents. Oncogene 16: 22292241.
  • Arizti P, Fang L, Park I, Yin Y, Solomon E, Ouchi T, Aaronson S, Lee SW. 2000. Tumor suppressor p53 is required to modulate BRCA1 expression. Mol Cell Biol 20: 74507459.
  • Aust AE, Falahee KJ, Maher VM, McCormick JJ. 1981. Identifying human cells capable of metabolizing various classes of carcinogens. J Supramol Struct Cell Biochem 16: 269279.
  • Bral CM, Ramos KS. 1997. Identification of benzo[a]pyrene-inducible cis-acting elements within c-Ha-ras transcriptional regulatory sequences. Mol Pharmacol 52: 974982.
  • Butler AP, Johnson DG, Kumar AP, Narayan S, Wilson SH, MacLeod MC. 1997. Disruption of transcription in vitro and gene expression in vivo by DNA adducts derived from a benzo[a]pyrene diol epoxide located in heterologous sequences. Carcinogenesis 18: 239244.
  • Chen Y, Farmer AA, Chen CF, Jones DC, Chen PL, Lee WF. 1996. BRCA1 is a 220-kDa nuclear phosphoprotein that is expressed and phosphorylated in a cell cycle-dependent manner. Cancer Res 56: 31683172.
  • Deng CX, Brodie SG. 2000. Roles of BRCA1 and its interacting proteins. Bioessays 22: 728737.
  • Denissenko MF, Pao A, Tang M, Pfeifer GP. 1996. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in p53. Science 274: 430432.
  • Dipple A, Khan QA, Page JE, Ponten I, Szeliga J. 1999. DNA reactions, mutagenic action and stealth properties of polycyclic aromatic hydrocarbon carcinogens [review]. Int J Oncol 14: 103111.
  • Dohr O, Vogel C, Abel J. 1995. Different response of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-sensitive genes in human breast cancer MCF-7 and MDA-MB-231 cells. Arch Biochem Biophys 321: 405412.
  • Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, Tavtigian S, Bennett LM, Haugen-Strano A, Swensen J, Miki Y, Eddington K, McClure M, Frye C, Weaver-Feldhaus J, Ding W, Gholami Z, Soderkvist P, Terry L, Johanwar S, Berchuck A, Iglehart JD, Marks J, Ballinger DG, Barrett JC, Skolnick MH, Kamb A, Wiseman R. 1994. BRCA1 mutations in primary breast and ovarian carcinomas. Science 266: 120122.
  • Gasiewicz TA, Rucci G. 1991. α-Naphthoflavone acts as an antagonist of 2,3,7,8-tetrachlorodibenzo-p-dioxin by forming an inactive complex with the Ah receptor. Mol Pharmacol 40: 607612.
  • Gowen LC, Avrutskaya AV, Latour AM, Koller BH, Leadon SA. 1998. BRCA1 required for transcription-coupled repair of oxidative DNA damage. Science 281: 10091012.
  • Greenblatt MS, Bennett WP, Hollstein M, Harris CC. 1994. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 48554878.
  • Gudas JM, Nguyen H, Li T, Cowan KH. 1995. Hormone-dependent regulation of BRCA1 in human breast cancer cells. Cancer Res 55: 444450.
  • Hattemer-Frey HA, Travis CC. 1991. Benzo-a-pyrene. Environmental partitioning and human exposure. Toxicol Ind Health 7: 141157.
  • Henry EC, Gasiewicz TA. 1993. Transformation of the aryl hydrocarbon receptor to a DNA-binding form is accompanied by release of the 90 kDa heat-shock protein and increased affinity for 2,3,7,8-tetrachlorodibenzo-p-dioxin. Biochem J 294: 95101.
  • Hoivik D, Willett K, Wilson C, Safe S. 1997. Estrogen does not inhibit 2,3,7,8-tetrachlorodibenzo-p-dioxin-mediated effects in MCF-7 and Hepa 1c1c7 cells. J Biol Chem 272: 3027030274.
  • Holt JT, Thompson ME, Szabo C, Robinson-Benion C, Arteaga CL, King MC, Jensen RA. 1996. Growth retardation and tumor inhibition by BRCA1. Nat Genet 12: 298302.
  • Hord NG, Perdew GH. 1994. Physicochemical and immunocytochemical analysis of the aryl hydrocarbon receptor nuclear translocator: characterization of two monoclonal antibodies to the aryl hydrocarbon receptor nuclear translocator. Mol Pharmacol 46: 618626.
  • Jeffy BD, Schultz EU, Selmin O, Gudas JM, Bowden GT, Romagnolo D. 1999. Inhibition of BRCA-1 expression by benzo[a]pyrene and its diol epoxide. Mol Carcinogen 26: 100118.
  • Jeffy BD, Chen EJ, Gudas JM, Romagnolo DF. 2000. Disruption of cell cycle kinetics by benzo[a]pyrene: inverse expression patterns of BRCA-1 and p53 in MCF-7 cells arrested in S and G2. Neoplasia 2: 460470.
  • Jeffy BD, Chirnomas RB, Chen EJ, Gudas JM, Romagnolo DF. 2002. Activation of the aromatic hydrocarbon receptor pathway is not sufficient for transcriptional repression of BRCA-1: requirements for metabolism of benzo[a]pyrene to BPDE. Cancer Res 62: 113121.
  • Kazerouni N, Sinha R, Hsu CH, Greenberg A, Rothman N. 2001. Analysis of 200 food items for benzo[a]pyrene and estimation of its intake in an epidemiologic study. Food Chem Toxicol 39: 423436.
  • Khan QA, Vousden KH, Dipple A. 1997. Cellular response to DNA damage from a potent carcinogen involves stabilization of p53 without induction of p21(waf1/cip1). Carcinogenesis 18: 23132318.
  • Khan QA, Agarwal R, Seidel A, Frank H, Vousden KH, Dipple A. 1998. DNA adduct levels associated with p53 induction and delay of MCF-7 cells in S phase after exposure to benzo[g]chrysene dihydrodiol epoxide enantiomers. Mol Carcinogen 23: 115120.
  • Kinzler KW, Vogelstein B. 1997. Cancer-susceptibility genes: gatekeepers and caretakers. Nature 386: 761763.
  • Krishnan V, Porter W, Santostefano M, Wang X, Safe S. 1995. Molecular mechanism of inhibition of estrogen-induced cathepsin-D gene expression by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in MCF-7 Cells. Mol Cell Biol 15: 67106719.
  • Larson JS, Tonkinson JL, Lai MT. 1997. A BRCA1 mutant alters G2-M cell cycle control in human mammary epithelial cells. Cancer Res 57: 33513355.
  • Lijinsky W. 1991. The formation and occurrence of polynuclear aromatic hydrocarbons associated with food. Mutat Res 259: 251261.
  • MacLachlan TK, Dash BC, Dicker DT, El-Deiry WS. 2000. Repression of BRCA-1 through a feedback loop involving p53. J. Biol Chem 275: 3186931875.
  • MacLeod MC, Powell KL, Tran N. 1995. Binding of the transcription factor Sp1 to non-target sites in DNA modified by benzo[a]pyrene diol epoxide. Carcinogenesis 16: 975983.
  • Marks JR, Huper G, Vaughn JP, Davis PL, Norris J, McDonnell DP, Wiseman RW, Futreal PA, Iglehart JD. 1997. BRCA1 expression is not directly responsive to estrogen. Oncogene 14: 115121.
  • Merchant M, Arellano L, Safe S. 1990. The mechanism of action of α-naphthoflavone as an inhibitor of 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced CYP1A1 gene expression. Arch Biochem Biophys 281: 8489.
  • Mietz JA, Unger T, Huibregtse JM, Howley PM. 1992. The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein. EMBO J 11: 50135020.
  • Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen-Strano A, Katcher H, Yakumo K, Ghalami Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayananth P, Ward J, Tonin P, Narod S, Pam K, Bristow PK, Norris FH, Helvering L, Morrison P, Rosteck P, Lai M, Barrett JC, Lewis C, Neuhausen S, Cannon-Albright L, Goldgar D, Wiseman R, Kamb A, Skolnick MH. 1994. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266: 6671.
  • Minamoto T, Mai M, Ronai Z. 1999. Environmental factors as regulators and effectors of multistep carcinogenesis. Carcinogenesis 20: 519527.
  • Moore M, Wang X, Lu YF, Wormke M, Craig A, Gerlach JH, Burghardt R, Barhoumi R, Safe S. 1994. Benzo[a]pyrene-resistant MCF-7 human breast cancer cells: a unique aryl hydrocarbon-nonresponsive clone. J Biol Chem 269: 1175111759.
  • Nebert DW, Petersen DD, Fornace AJ Jr. 1990. Cellular responses to oxidative stress: the [Ah] gene battery as a paradigm. Environ Health Perspect 88: 1325.
  • Peto J, Collins N, Barfoot R, Seal S, Warren W, Rahman N, Easton DF, Evans C, Deacon J, Stratton MR. 1999. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 91: 943949.
  • Piskorska-Pliszczynska J, Keys B, Safe S, Newman MS. 1986. The cytosolic receptor binding affinities and AHH induction potencies of 29 polynuclear aromatic hydrocarbons. Toxicol Lett 34: 6774.
  • Quan T, Reiners JJ Jr, Culp SJ, Richter P, States JC. 1995. Differential mutagenicity and cytotoxicity of (+/−)-benzo[a]pyrene-trans-7,8-dihydrodiol and (+/−)-anti-benzo[a]pyrene-trans-7,8-dihydrodiol-9,10-epoxide in genetically engineered human fibroblasts. Mol Carcinog 12: 91102.
  • Rajan JV, Wang M, Marquis ST, Chodosh LA. 1996. BRCA2 is coordinately regulated with BRCA1 during proliferation and differentiation in mammary epithelial cells. Proc Natl Acad Sci USA 93: 1307813083.
  • Rao VN, Shao N, Ahmad M, Shyam C, Reddy P. 1996. Antisense RNA to the putative tumor suppressor gene BRCA1 transforms mouse fibroblasts. Oncogene 12: 523528.
  • Richter CA, Tillit DE, Hannick M. 2001. Regulation of subcellular localization of the aryl hydrocarbon receptor (AhR). Arch Biochem Biophys 389: 207217.
  • Romagnolo D, Annab LA, Lyon TT, Risinger JI, Terry LA, Barrett JC, Afshari CA. 1998. Estrogen upregulation of expression of BRCA-1 with no effect on localization. Mol Carcinog 22: 102109.
  • Ronai Z, Gradia S, el-Bayoumy K, Amin S, Hecht SS. 1994. Contrasting incidence of ras mutations in rat mammary and mouse skin tumors induced by anti-benzo[c]phenanthrene-3,4-diol-1,2-epoxide. Carcinogenesis 15: 21132116.
  • Safe S. 2001. Molecular biology of the Ah receptor and its role in carcinogenesis. Toxicol Lett 120: 17.
  • Safe S, Krishnan V. 1995. Chlorinated hydrocarbons: estrogens and antiestrogens. Toxicol Lett 82/83: 731736.
  • Safe S, Qin C, McDougal A. 1999. Development of selective aryl hydrocarbon receptor modulators (SAhRMs) for treatment of breast cancer. Exp Opin Invest Drugs 8: 13851396.
  • Scherer G, Frank S, Riedel K, Meger-Kossien I, Renner T. 2000. Biomonitoring of exposure to polycyclic aromatic hydrocarbons of nonoccupationally exposed persons. Cancer Epidemiol Biomarkers Prev 9: 373380.
  • Scully R, Chen J, Ochs RL, Keegan K, Hoekstra M, Feunteun J, Livingston DM. 1997. Dynamic changes of BRCA1 subnuclear localization and phosphorylation state are initiated by DNA damage. Cell 90: 120.
  • Shackelford RE, Kaufmann WK, Paules RS. 1999. Cell cycle control, checkpoint mechanisms, and genotoxic stress. Environ Health Perspect 107: 524.
  • Sharan SK, Morimatsu M, Albrecht U, Lim DS, Regel E, Dinh C, Sands A, Eichele G, Hasty P, Bradley A. 1997. Embyonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking BRCA2. Nature 386: 804810.
  • Shih HA, Nathanson KL, Seal S, Collins N, Stratton MR, Rebbeck TR, Weber BL. 2000. BRCA1 and BRCA2 mutations in breast cancer families with multiple primary cancers. Clin Cancer Res 6: 42594264.
  • Somasundaram K, Zhang H, Zeng Y, Houvras Y, Peng Y, Zhang H, Wu G, Licht JD, Weber BL, El-Deiry W. 1997. Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiPI. Nature 389: 187190.
  • Spink DC, Spink BC, Cao JQ, DePasquale JA, Pentecost BT, Fasco MJ, Li Y, Sutter TR. 1998. Differential expression of CYP1A1 and CYP1B1 in human breast epithelial cells and breast tumor cells. Carcinogenesis 19: 291298.
  • Szeliga J, Hilton BD, Chmurny GN, Krzeminski J, Amin S, Dipple A. 1997. Characterization of DNA adducts formed by the four configurationally isomeric 5,6-dimethylchrysene 1,2-dihydrodiol 3,4-epoxides. Chem Res Toxicol 10: 378385.
  • Thomas JE, Smith M, Tonkinson JL, Rubinfeld B, Polakis P. 1997. Induction of phosphorylation on BRCA1 during the cell cycle and after DNA damage. Cell Growth Differ 8: 801809.
  • Thompson ME, Jensen RA, Obermiller PS, Paige PS, Holt DL. 1995. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet 9: 444450.
  • Wei Q, Gu J, Cheng L, Bondy ML, Jiang H, Hong WK, Spitz MR. 1996. Benzo[a]pyrene diol epoxide-induced chromosomal aberrations and risk of lung cancer. Cancer Res 56: 39753979.
  • Wei SJ, Chang RL, Wong CQ, Bhachech N, Cui XX, Hennig E, Yagi H, Sayer JM, Jerina DM, Preston BD, Conney AH. 1991. Dose-dependent differences in the profile of mutations induced by an ultimate carcinogen from benzo[a]pyrene. Proc Natl Acad Sci USA 88: 1122711230.